Sugi Predict

Sugi Predict / Compounds / SCHEMBL837668

SCHEMBL837668

SCHEMBL837668

O=C(O)c1cc(Br)c2ccccc2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 2/20 0.58
▸ GRM2 Q14416 2/20 0.53
▸ MGAM O43451 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ PDE10A Q9Y233 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ MCL1 Q07820 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ CDK9 P50750 1/20 0.43
▸ DYRK1A Q13627 1/20 0.43
▸ DYRK2 Q92630 1/20 0.43
▸ DYRK1B Q9Y463 1/20 0.43
▸ HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL759037 0.86 GRM2 (0.70) GRM2ALDH1A1
SCHEMBL1694287 0.82 KDM4E (0.52) ALOX15GRM2ALDH1A1HPGDHSD17B10
SCHEMBL32681649 0.82 KDM4E (0.52) ALOX15GRM2ALDH1A1HPGDHSD17B10
Transtorine SCHEMBL17596601 0.79 ALOX15 (0.60) ALOX15MGAMALDH1A1HPGDHSD17B10
SCHEMBL29450085 0.79 KDM4E (0.64) ALOX15MGAMALDH1A1HPGDHSD17B10
Transtorine SCHEMBL22979 0.79 ALOX15 (0.60) ALOX15MGAMALDH1A1HPGDHSD17B10
SCHEMBL69125 0.79 KDM4E (0.64) ALOX15MGAMALDH1A1HPGDHSD17B10
SCHEMBL6212315 0.79 GRM2 (0.43) ALOX15GRM2ALDH1A1HPGDHSD17B10
SCHEMBL27716049 0.79 ESR1 (0.57) ALOX15GRM2MGAMALDH1A1SMN1; SMN2
SCHEMBL2222620 0.78 SMN1; SMN2 (0.60) ALOX15ALDH1A1SMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023151641-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 — — WO disclosed
US-20220315565-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2022-10-06 — — US disclosed
US-11299484-B2 Inhibiting fatty acid synthase (FASN) FORMA THERAPEUTICS, INC. (US) 2022-04-12 — — US disclosed
US-11299484-B2 Inhibiting fatty acid synthase (FASN) FORMA THERAPEUTICS, INC. (US) 2022-04-12 — — US disclosed
CN-113329748-A Inhibition of Fatty Acid Synthase (FASN) 福马治疗股份有限公司 2021-08-31 — — CN disclosed
US-20210024508-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2021-01-28 — — US disclosed
US-20210024508-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2021-01-28 — — US disclosed
US-10875848-B2 Inhibiting fatty acid synthase (FASN) FORMA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-20200115368-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2020-04-16 — — US disclosed
EP-3636637-A1 INHIBITING FATTY ACID SYNTHASE (FASN) Forma Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
EP-1664025-B1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2007-09-19 — — EP disclosed
CN-1951939-A Novel pyrrole derivatives as pharmaceutical agents LILLY CO ELI (US) 2007-04-25 — — CN disclosed
CN-1882568-A Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2006-12-20 — — CN disclosed
WO-2006133326-A1 INHIBITORS OF HCV REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2006-12-14 — — WO disclosed
US-20060276511-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-12-07 — — US disclosed
US-20060223801-A1 Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2006-10-05 — — US disclosed
CN-1269820-C Novel pyrrole derivatives as medicaments LILLY CO ELI (US) 2006-08-16 — — CN disclosed
EP-1664025-A1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY AstraZeneca AB (SE) 2006-06-07 — — EP disclosed
WO-2005026149-A1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2005-03-24 — — WO disclosed
CN-1511157-A Novel pyrrole derivatives as medicaments — 2004-07-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223801-A1 Pyrrol derivatives with antibacterial activity PEF1, PEPD, PELP1 ALOX15 1295/4885GRM2 4638/4885MGAM 541/4885
US-10875848-B2 Inhibiting fatty acid synthase (FASN) FASN, SCD, FADS1 ALOX15 89/4885GRM2 2003/4885MGAM 1662/4885
US-20210024508-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 ALOX15 89/4885GRM2 2003/4885MGAM 1662/4885
US-20200115368-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 ALOX15 89/4885GRM2 2003/4885MGAM 1662/4885
US-20060276511-A1 Inhibitors of HCV replication EIF2AK2, RTF2, GTF3C1 ALOX15 3831/4885GRM2 4846/4885MGAM 3135/4885
US-20220315565-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 ALOX15 89/4885GRM2 2003/4885MGAM 1662/4885
US-11299484-B2 Inhibiting fatty acid synthase (FASN) FASN, SCD, FADS1 ALOX15 89/4885GRM2 2003/4885MGAM 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.